| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
112,161 |
109,746 |
$6.65M |
| 27096 |
|
17,937 |
10,320 |
$5.80M |
| 64483 |
|
13,050 |
7,667 |
$2.05M |
| 64484 |
|
8,576 |
4,480 |
$1.49M |
| 76881 |
|
18,579 |
18,268 |
$1.37M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
25,212 |
25,152 |
$1.31M |
| 76942 |
|
17,852 |
17,526 |
$907K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
17,687 |
17,286 |
$857K |
| 99152 |
|
12,680 |
12,150 |
$681K |
| 20610 |
|
8,506 |
6,762 |
$459K |
| 99245 |
|
2,197 |
2,189 |
$353K |
| 62321 |
|
1,055 |
1,017 |
$265K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,279 |
2,263 |
$224K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
1,743 |
1,738 |
$202K |
| 20553 |
|
2,982 |
2,879 |
$196K |
| 95886 |
|
1,039 |
536 |
$117K |
| 95913 |
|
271 |
271 |
$102K |
| 64493 |
|
710 |
468 |
$94K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
18,296 |
18,217 |
$93K |
| 96132 |
|
408 |
408 |
$68K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
476 |
474 |
$57K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,606 |
1,491 |
$53K |
| 95912 |
|
154 |
151 |
$49K |
| 64494 |
|
672 |
445 |
$47K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,889 |
3,813 |
$45K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
4,925 |
4,488 |
$44K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
209 |
206 |
$41K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
6,750 |
6,714 |
$39K |
| 0012A |
|
904 |
904 |
$35K |
| J3490 |
Unclassified drugs |
4,357 |
4,200 |
$31K |
| 0011A |
|
906 |
906 |
$30K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
480 |
477 |
$25K |
| 96138 |
|
372 |
371 |
$19K |
| 0001A |
|
474 |
474 |
$19K |
| 0002A |
|
444 |
444 |
$18K |
| 64635 |
|
86 |
65 |
$17K |
| 92551 |
|
1,908 |
1,905 |
$15K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
306 |
305 |
$14K |
| 95991 |
|
55 |
50 |
$14K |
| 64495 |
|
145 |
99 |
$11K |
| 20552 |
|
161 |
136 |
$9K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
297 |
260 |
$7K |
| 0013A |
|
162 |
161 |
$6K |
| 0031A |
|
156 |
156 |
$6K |
| 95885 |
|
76 |
38 |
$6K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
89 |
89 |
$6K |
| 0072A |
|
136 |
136 |
$5K |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
1,133 |
1,085 |
$5K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
102 |
101 |
$5K |
| 81003 |
|
1,054 |
1,010 |
$4K |
| 86328 |
|
132 |
127 |
$4K |
| 0071A |
|
96 |
96 |
$4K |
| 64636 |
|
62 |
39 |
$4K |
| 99243 |
|
42 |
42 |
$4K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
65 |
64 |
$4K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
42 |
42 |
$3K |
| 63650 |
|
24 |
12 |
$3K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
42 |
41 |
$3K |
| 99384 |
|
14 |
14 |
$2K |
| 99173 |
|
1,045 |
1,044 |
$2K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
97 |
29 |
$2K |
| 85018 |
|
471 |
467 |
$2K |
| 90697 |
|
14 |
14 |
$1K |
| 0003A |
|
27 |
27 |
$1K |
| L3908 |
Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf |
12 |
12 |
$517.88 |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
101 |
101 |
$512.55 |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
92 |
29 |
$506.68 |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
96 |
28 |
$483.36 |
| 90670 |
|
30 |
30 |
$465.13 |
| G8731 |
Pain assessment using a standardized tool is documented as negative, no follow-up plan required |
5,594 |
5,306 |
$411.12 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
12 |
12 |
$391.86 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
5,597 |
5,308 |
$275.99 |
| 83655 |
|
45 |
44 |
$265.63 |
| 87400 |
|
50 |
24 |
$145.34 |
| 90658 |
|
31 |
24 |
$120.38 |
| 99442 |
|
236 |
233 |
$66.59 |
| 96127 |
|
12 |
12 |
$48.10 |
| J1330 |
Injection, ergonovine maleate, up to 0.2 mg |
179 |
179 |
$6.05 |
| 3074F |
|
34 |
34 |
$0.00 |
| 99422 |
|
48 |
48 |
$0.00 |
| G8539 |
Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment |
37 |
37 |
$0.00 |
| 3078F |
|
31 |
31 |
$0.00 |